Torre DA

Language: Spanish
References: 7
Page: 483
PDF size: 57.76 Kb.

Text Extraction

No Abstract

REFERENCES

1. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 1121-5.

2. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 28(Suppl.): S69-89.

3. Uriz J, Ginés P, Cardenas A, et al. Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.

4. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midrodrine and octreotide. Hepatology 1999; 29: 1690-7.

5. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.

6. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 2002; 36: 941-8.

7. Lee S. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy. Hepatology 2003; 38: 1089-91.